Rithm Capital Corp. (RITM) Form 10-Q — Aug 4, 2026
Rithm Capital's Q2 2026 GAAP results deteriorated sharply: total revenue rose to $1.28 billion from $1.22 billion a year ago, but net income attributable to common stockholders fell to $20.2 million, or $0.04 per share, from $283.9 million, or $0.54 per share, in Q2 2025. The decline was driven by a $392.9 million negative fair value change on MSRs and MSR financing receivables net of economic hedges (including $227.2 million of hedge losses), higher interest expense, and a jump in compensation and depreciation tied to recent acquisitions.
Key figures
- Eps
- 0.04
- Revenue
- 1282281000
- Net Income
- 67913000
- Total Debt
- 29943585000
- Revenue Yoy
- +5.1% YoY (Q2 2026 vs Q2 2025, derived from stated figures of $1,282,281K vs $1,219,594K)
- Total Assets
- 54108868000
- Cash Position
- 2454708000
- Shares Outstanding
- 558407031
- Eps 1h 2026
- 0.16
- Revenue 1h 2026
- 2666991000
- Basic eps q2 2025
- 0.54
- Crestline goodwill
- $182.8 million
- Msr carrying value
- 11091483000
- Msr underlying upb
- $596.8 billion
- Net income 1h 2026
- 177391000
- Diluted eps q2 2026
- 0.04
- Third party serviced upb
- $253.7 billion
- Loans subject to repurchase
- $4.3 billion
- Preferred dividends q2 2026
- 36098000
- Dividends declared per share
- 0.25
- Onity msr upb pending consents
- $8.0 billion
- Preferred shares issued 1h 2026
- 10000000
- Asset management revenue q2 2025
- 95008000
- Asset management revenue q2 2026
- 142228000
- Gain on originated loans q2 2026
- 207006000
- Crestline acquisition consideration
- $324.7 million
- Commercial real estate revenue q2 2026
- 182130000
- Net income attributable to common q2 2025
- 283899000
- Net income attributable to common q2 2026
- 20193000
- Elecor paramount acquisition consideration
- $1.8 billion
Price after filing
Close on the filing date to close N calendar days later (from $10.25). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.